



**Memorandum**

**FEB 27 2004**

Date:  
From: Interdisciplinary Scientist/Botanist, Division of Dietary Supplement Programs,  
Office of Nutritional Products, Labeling and Dietary Supplements, HFS-810  
Subject: 75-Day Premarket Notification of New Dietary Ingredients  
To: Dockets Management Branch, HFA-305


Subject of the Notification:

Firm: Conseco Co, Ltd.

Date Received by FDA: 10/08/03

90-Day Date: 1/06/04

In accordance with the requirements of section 413(a) of the Federal Food, Drug, and Cosmetic Act, the attached 75-day premarket notification and related correspondence for the aforementioned substance should be placed on public display in docket number 95S-0316 as soon possible since it is past the 90-day date. Thank you for your assistance.

  
Tanya Jackson, Interdisciplinary Scientist, HFD 810

Attachments

955-0316

RPT 212



DEC 19 2003

Han Xu, M.D.  
Senior Researcher  
Conseco Sea Buckthorn Co., Ltd  
Jia 1 Fuxing Road, Haidian District  
Beijing 100038  
P.R. China

Dear Dr. Xu:

This is to inform you that the notification that you submitted pursuant to 21 U.S.C. 350b(a)(2)(section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act (the Act)) was filed by the Food and Drug Administration (FDA) on October 8, 2003. Your notification concerns the substance called "Conseco Brand Sea Buckthorn Granules" that you intend to market as a new dietary ingredient.

According to the notification, you intend to sell 15 g bags of your new dietary ingredient, Conseco Brand Sea Buckthorn Granules, which is a dietary supplement substance obtained from the fruits of Hippophae rhamnoides L. You recommend taking 15 g (one bag), mixed with warm water, three times daily for a total daily intake of 45 g.

Under 21 U.S.C. 350b(a), the manufacturer or distributor of a dietary supplement containing a new dietary ingredient that has not been present in the food supply as an article used for food in a form in which the food has not been chemically altered must submit to FDA, at least 75 days before the dietary ingredient is introduced or delivered for introduction into interstate commerce, information that is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing such new dietary ingredient will reasonably be expected to be safe. FDA reviews this information to determine whether it provides an adequate basis for such a conclusion. Under section 350b(a)(2), there must be a history of use or other evidence of safety establishing that the new dietary ingredient, when used under the conditions recommended or suggested in the labeling of the dietary supplement, will reasonably be expected to be safe. If this requirement is not met, the dietary supplement is considered to be adulterated under 21 U.S.C. 342(f)(1)(B) because there is inadequate information to provide reasonable assurance that the new dietary ingredient does not present a significant or unreasonable risk of illness or injury.

FDA has carefully considered the information in your submission, and the agency has concerns about the evidence on which you rely to support your conclusion that a dietary supplement containing Conseco Brand Sea Buckthorn Granules will reasonably be expected to be safe.

Based on the notification, it is unclear how the information submitted relates qualitatively or quantitatively to the dietary supplement containing Conseco Brand Sea Buckthorn Granules. The notification did not clearly characterize the test substances used in the referenced studies or how these studies are relevant to evaluating the safe use of Conseco Brand Sea Buckthorn Granules under the recommended conditions of use. For example, the notification contains the results of one (1) acute and one (1) 60-day safety study conducted with a substance called "Sea Buckthorn Granules", however, the notification does not specify that "Sea Buckthorn Granules" is the same as Conseco Brand Sea Buckthorn Granules.

For the reasons discussed above, the information in your submission does not provide an adequate basis to conclude that the Conseco Brand Sea Buckthorn Granule product, when used under the conditions recommended or suggested in the labeling of your product, will reasonably be expected to be safe. Therefore, your product may be adulterated under 21 U.S.C. 342(f)(1)(B) as a dietary supplement that contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. Introduction of such a product into interstate commerce is prohibited under 21 U.S.C. 331(a) and (v).

Your notification will be kept confidential for 90 days after the filing date of October 8, 2003. After the 90-day date, the notification will be placed on public display at FDA's Docket Management Branch in docket number 95S-0316. Prior to that date, you may wish to identify in writing specifically what information you believe is proprietary, trade secret or otherwise confidential for FDA's consideration.

If you have any questions concerning this matter, please contact Victoria Lutwak at (301) 436-2375.

Sincerely yours,



Susan J. Walker, M.D.  
Division Director  
Division of Dietary Supplement Programs  
Office of Nutritional Products, Labeling  
and Dietary Supplements  
Center for Food Safety  
and Applied Nutrition